Alzamend Neuro CEO, Stephan Jackman Says In 2023 Co Is Looking To Submit Three INDs For The FDA For Bipolar Disorder, Major Depressing Disorder, And PTSD
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro's CEO, Stephan Jackman, has announced that the company plans to submit three Investigational New Drug applications (INDs) to the FDA in 2023. These applications will be for treatments of bipolar disorder, major depressive disorder, and PTSD.
June 28, 2023 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alzamend Neuro's announcement of plans to submit three INDs to the FDA in 2023 could potentially boost investor confidence and the company's stock price in the short term.
The announcement of Alzamend Neuro's plans to submit three INDs to the FDA in 2023 indicates the company's progress in developing new treatments. This could potentially attract more investors, leading to an increase in the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100